International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

Role of AI and Machine Learning in Drug Discovery and Formulation

[1]Vishal Wagh, [2]Sonali Kalam, [3]Dr. Gajanan Sanap
1Student, 2Assistance professor, 3Principal
1,2,3 Department of Pharmacy
Late Bhagirathi Yashwantrao Collage of Pharmacy, Pathri

Date of Submission: 10-12-2024 Date of Acceptance: 20-12-2024

I. INTRODUCTION

Recently, the fusion of Artificial Intelligence (AI) and Machine Learning (ML) techniques has become a significant catalyst in revolutionizing pharmaceutical formulation design. This merging of state-of-the-art computational methods with traditional pharmaceutical sciences offers unprecedented opportunities for driving innovation and streamlining processes across the drug development spectrum.[1] This overview aims to delve into a comprehensive examination of the evolving role of AI and ML in pharmaceutical formulation design, encompassing underlying necessities, historical context, methodological complexities, recent progressions, and future trajectories.[2] Historically, conventional methods of pharmaceutical formulation design have relied heavily on laborious and repetitive processes, characterized by empirical experimentation and trial-and-error approaches. However, the increasingly complex landscape of contemporary drug development, fueled by the pursuit of personalized medicine and the rise in intricate diseases,demands a fundamental transition towards more efficient and systematic methodologies.[3] This drive for innovation has spurred the exploration of AI and ML technologies as promising avenuesto streamline formulation design processes, optimize drug delivery systems, and enhance therapeutic outcomes.[4] Meta-analyses examining AI-driven drug discovery and formulation design efforts consistently underscore the transformative potential inherent in these technologies. Through the utilization of vast datasets and advanced algorithms, AI and ML platforms enable rapid identification of lead compounds, precise prediction of physicochemical properties, and refinement of drug delivery methods.[5] For example, a comprehensive metaanalysis synthesized insights from various research endeavors, highlighting the effectiveness of AI in rational drug design and formulation improvement.[6] Moreover, empirical studies have demonstrated the efficacy of ML algorithms in developing controlled-release formulations, designing nanocarrier- based delivery systems, and customizing personalized dosage regimens.[7] The growing body of literature documenting AI and ML applications in pharmaceutical formulation design signifies a noticeable shift toward data-driven and predictive methodologies.[8] However, despite significant advancements, persistent challenges such as ensuring data quality, navigating regulatory requirements, and addressing ethical concerns remain substantial obstacles.[9] Nonetheless, the ongoing advancement of AI and ML technologies, supported by interdisciplinary collaborations among pharmaceutical scientists, computer engineers, and regulatory entities, holds great promise for reshaping the landscape of drug development and healthcare delivery.

Application of AI and ML in Rational Drug Design Molecular Docking and Virtual Screening

Molecular docking and virtual screening, pivotal components of rational drug design, have undergone a transformative evolution with the integration of Artificial Intelligence (AI) and Machine Learning (ML) techniques. Meta-analyses have demonstrated a significant enhancement in hit rates and binding affinity prediction accuracy when AI and ML algorithmsare employed. Novel approaches, including the integration of deep learning models like convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have been introduced to improve predictive performance.[15] These approaches augment traditional algorithms such as AutoDock and DOCK, optimizing scoring functions for better accuracy. Moreover, meta-analyses underscore the superiority of AI-driven docking algorithms in predicting binding affinity and enriching active compounds across diverse

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

drug targets.[16]

Case studies where AI-driven molecular docking expedites lead compound identification across various therapeutic areas illustrate the utility of virtual screening coupled with machine learning-based scoring functions in identifying potential antiviral drug candidates, particularly in the context of the COVID-19 pandemic.[17] In summary, these advancements underscore the indispensable role of AI and ML in revolutionizing molecular docking and virtual screening, enhancing their efficiency, accuracy, and impact in rational drug design endeavors.

QSAR/QSPR Models for Drug Activity Prediction

Quantitative Structure-Activity Relationship (QSAR) and Quantitative Structure-Property Relationship (QSPR) models stand as crucial pillars in drug discovery, enabling the prediction of a compound's biological activity or physicochemical properties based on its molecular structure.[19] With the integration of Artificial Intelligence (AI) and Machine Learning (ML) techniques, QSAR/QSPR modeling has witnessed a profound transformation, marked by enhanced prediction accuracy and efficiency in lead optimization and compound design.[20] Novel methodologies, such as the implementation of deep learning architectures like recurrent neural networks (RNNs) and graph convolutional networks (GCNs), have further elevated predictive performance.[21] These models typically correlate molecular descriptors with biological activities or properties using AI and ML algorithms, such as random forests and support vector machines, trained on extensive datasets. Advanced feature selection techniques enhance model interpretability and generalization.[22] Meta- analyses have highlighted the superior predictive power of AI-driven QSAR/QSPR models across diverse chemical datasets and target classes.[23] The practical utility of AI-driven QSAR/QSPR models in lead optimization, hit prioritization, and formulation design, cement their indispensable role in modern drug discovery efforts across various therapeutic domains.

De Novo Drug Design

De Novo Drug Design is a transformative strategy in drug discovery, focused on creating novel compounds customized to target specific diseases.[25] It encompasses several key stages, beginning with defining the molecular target and determining its three-dimensional structure.

Computational tools, including molecular docking and machine learning algorithms, are then utilized to explore chemical space and identify potential drug candidates.[26] These candidates undergo rigorous filtering and optimization processes to enhance their efficacy and safety profiles.[25]

Notable successes in this field include the development of HIV protease inhibitors and GPCR modulators, demonstrating the potential of De Novo Drug Design to yield innovative therapeutics.[26-By integrating computational intelligence with chemical synthesis, this approach offers the promise of accelerating drug discovery and addressing unmet medical needs.[28] However, challenges persist in optimizing compounds and navigating regulatory approval processes.[29]

Continued research efforts are essential to fully realize the potential of De Novo Drug Design in revolutionizing healthcare and advancing precision medicine initiatives. De Novo Drug Design holds immense promise for overcoming the limitations of traditional drug discovery methods by directly synthesizing compounds with desired properties.[30] Despite its potential, ongoing research is crucial to address challenges related to compound optimization, experimental validation, and regulatory approval. [31] By harnessing the power of computational intelligence and chemical synthesis, De Novo Drug Design represents a pivotal approach to transforming healthcare and advancing precision medicine initiatives.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

Fig. 1: Process of Molecular Docking and Virtual Screening (red), QSAR/QSPR modeling(violet), and De Novo Drug Design (green)



Table 2: Basic information about various drug design approaches, ML models, and software toolsused in the field of pharmaceutical research

Software	Description	Features	Examples
Schrodinger Suite	Suite for drug discovery and materials science. Offers molecularmodeling, virtualscreening, and design tools.	Molecular docking: Predicts ligand binding to proteins. Virtual screening: Screens compound libraries.	Maestro, Glide, QSite, Prime

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

MOE (Molecular Operating	Integrated platformfor molecular modeling and drugdesign. Provides tools for visualization andanalysis.	Homology modeling: Predicts protein structures. QSAR modeling: Quantifies structure-activity relationships	MOE, MOEsaic
AutoDock	Open-source software for molecular docking. Predicts ligand binding affinitiesusing empirical forcefields.	Docking studies: Predicts bindingmodes and energies. Flexible ligand docking.	AutoDock Vina, AutoDock Tools
RDKit	Open-source cheminforma ticstoolkit for small molecules. Provides toolsfor molecular fingerprintin g and	Cheminform atics: Tools for chemical structure analysis. Substructure searching.	Cheminform atics, Molecular descriptors

Optimization of Drug Delivery Systems using AI and ML

Formulation Optimization

Pharmaceutical researchers begin by gathering extensive datasets on drug compounds, excipients,and formulation characteristics, utilizing AI algorithms to preprocess and analyze the data. Through feature selection and modeling techniques, key variables influencing formulation outcomes are identified, and machine learning models predict various properties such as drug release kinetics and stability. Optimization algorithms like genetic algorithms and simulated annealing are then employed to find the optimal combination of formulation parameters. Experimental validation using techniques like the Design of Experiments confirms model predictions and iterative refinement loops between experimental data and AI models improve predictive accuracy over time. Integration with scalability and manufacturability considerations ensures smooth translation from lab to commercial production, reducing costs and time- to-market.

Controlled Release Systems Design

Pharmaceutical researchers gather extensive data on drug properties, release kinetics, and formulation characteristics, employing AI algorithms to analyze and preprocess this information. Machine learning models are then developed to predict drug release kinetics from various controlled release systems, utilizing techniques like regression analysis and neural networks. Multi-objective optimization algorithms are used to balance conflicting objectives such as prolonging release duration and

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

maximizing drug loading efficiency. Real-time monitoring systems integrated into controlled release systems enable adaptive control, optimizing drug delivery dynamically. Personalized medicine approaches use machine learning models to tailor the controlled release systems to individual patient needs, enhancing therapeutic outcomes. Experimental validation and iterative refinement processes ensure the accuracy and improvement of controlled release systems over time, supported by AI-driven tools for regulatory compliance.

Nanoparticle Formulation Design

AI algorithms play a crucial role in material selection and screening for nanoparticle-based drug encapsulation, predicting properties like biocompatibility and stability. Machine learning models analyze vast datasets to identify promising materials, while computational techniques like QSAR modeling optimize material selection. Optimization algorithms refine nanoparticle properties suchas size and surface charge, enhancing drug targeting and release profiles. In silico testing simulates nanoparticle-drug interactions, guiding the design of effective formulations and reducing experimental trial-and- error. Experimental validation confirms predicted properties, with AI models refining based on validation data. Adaptive design strategies tailor nanoparticle formulations for personalized medicine, optimizing drug delivery for specific patient needs. AI- driven approaches also optimize nanoparticle manufacturing processes, ensuring scalability and consistent quality control for regulatory compliance.

Prediction of Physicochemical Properties

Solubility Prediction

In drug discovery and development, predicting solubility is crucial for assessing a compound's ability to dissolve and its potential efficacy as a drug. AI and ML techniques have become essential for this task due to the complexity of molecular interactions and the vast chemical space to explore. These models analyze large datasets containing chemical structures and solubility values, encompassing diverse compounds and chemical classes. Machine learningalgorithms like random forest and deep neural networks learn patterns between molecular features and solubility, leveraging descriptors like size, polarity, and hydrogen bonding capacity. After optimization, these models accurately predict solubility based solely on a compound's structural information. This predictive capability aids early-stage drug discovery by prioritizingcompounds with favorable solubility for further validation and optimization, offering advantages such as rapid screening, cost reduction, and identification of promising candidates. Integration of solubility prediction models into drug discovery workflows streamlines lead compound identification and accelerates therapeutic development.

Permeability Prediction

Predicting permeability is vital for assessing a drug candidate's ability to pass through biological barriers, influencing its ADME properties. AI and ML techniques are pivotal in developing predictive models for permeability using diverse datasets containing drug structures and experimental data. These models, employing algorithms like support vector machines and deep learning architectures, analyze molecular descriptors to accurately predict permeability. These descriptors include factors like molecular weight, lipophilicity, and hydrogen bonding capacity. After rigorous evaluation and optimization, the AI models can predict permeability based on a compound's structural information. This guides compound selection and optimization in drug development, enhancing the likelihood of clinical success.

Stability Prediction

Stability prediction is crucial in drug development for assessing a compound's endurance underdiverse environmental conditions. AI and ML techniques are increasingly utilized to forecast drug stability, aiding early issue detection and guiding formulation optimization. Leveraging large datasets encompassing various compounds and storage conditions, machine learning algorithms develop predictive models for stability. These models analyze molecular descriptors and formulation characteristics to identify patterns influencing stability outcomes. After rigorous evaluation and optimization, these AI models accurately predict stability based on compound structure and environmental factors. Predicted stability profiles inform formulation adjustments, recommending strategies to enhance stability and prolong shelf-life, thus ensuring pharmaceutical product safety and efficacy.

Formulation Stability Assessment with AI

Accelerated Stability Studies

Accelerated stability studies are pivotal in

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

pharmaceutical formulation development, providing insights into stability, degradation kinetics, and shelf-life estimation in a short timeframe. By subjecting formulations to exaggerated environmental conditions like elevated temperatures andhumidity, researchers can simulate long-term storage effects and predict behavior over time. AIand ML techniques enhance data analysis in these studies, processing data from experiments to identify patterns and degradation kinetics, and elucidating factors influencing stability and degradation pathways. Integration of AI models expedites issue identification, formulation optimization, and shelf-life determination, while predictive models extrapolate accelerated stability data to estimate long-term stability under normal storage conditions, aiding in establishing expiration dates for pharmaceutical products. Prediction of Degradation Pathways

Prediction of degradation pathways is crucial in pharmaceutical formulation development, providing insights into how drug compounds degrade over time and under varying conditions. AI and techniques enhance this process by analyzing large datasets containing chemical structures, formulation components, and experimental conditions. Machine learning algorithms identify patterns and relationships between formulation characteristics and degradation pathways, utilizing various techniques such as decision trees and neural networks. By anticipating chemical transformations like hydrolysis or oxidation, these models guide formulation optimization efforts, suggesting adjustments to enhance stability and prolong shelf- life. Integrating mechanistic knowledge into predictive models improves accuracy and interpretability, ensuring the safety, efficacy, and quality of pharmaceutical products through proactive mitigation of degradation mechanisms.

Shelf-life Prediction

Shelf-life prediction is crucial in pharmaceutical formulation development and regulatory approval, estimating how long a drug product maintains quality, safety, and efficacy under specified conditions. Utilizing AI and ML techniques offers significant advancements in estimating degradation kinetics and optimizing formulation parameters. AI models analyze extensive datasets containing formulation characteristics, degradation kinetics, and environmental factors to identify critical stability factors. Machine learning algorithms process this data to forecast degradation rates and predict shelf-life based on input features like temperature and humidity. By extrapolating accelerated stability data, these models establish expiration dates and guide formulation optimization efforts, suggesting adjustments to enhance stability and prolong shelf-life. Integrated with advanced statistical methods and expert knowledge, AI- driven approaches ensure the delivery of safe, effective, and high-quality pharmaceutical products by proactively addressing stability issues early in development.

ADVANTAGE:

1. By using AI algorithms to analyze data from large populations, they can be used to identify trends and patterns that can help predict the effectiveness of potential drug candidates for specific patient populations
2. which can help tailor treatments to the needs of individual patients.
3. AI algorithms can analyze complex relationships between drug properties, formulation components, and physiological factors to predict drug behavior at each scale.
4. AI-equipped technology can analyse data much faster than any human, including clinical studies, medical records and genetic information that can help medical professionals come to a diagnosis.

DISADVANTAGES:

1. Encouraging human laziness
2. Job displacement.

II. CONCLUSION:

By using AI algorithms to analyze data from large populations, they can be used to identify trends and patterns that can help predict the effectiveness of potential drug candidates for specific patient populations, which can help tailor treatments to the needs of individual patients.

REFERENCE:

[1]. Xu Y, Liu X, Cao X, Huang C, Liu E, Qian S, Liu X, Wu Y, Dong F, Qiu CW, Qiu J. Artificial intelligence: A powerful paradigm for scientific research. The Innovation. 2021Nov 28;2(4).

[2]. Zaslavsky J, Bannigan P, Allen C. Re-envisioning the design of nanomedicines: harnessing automation and artificial intelligence. Expert Opinion on Drug Delivery. 2023Feb 1;20(2):241-57.

[3]. Nowrin T. A systematic overview of the

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

impact of artificial intelligence in pharmaceutical science (Doctoral dissertation, Brac University).

[4]. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1916.

[5]. Younis HA, Eisa TA, Nasser M, Sahib TM, Noor AA, Alyasiri OM, Salisu S, Hayder IM, Younis HA. A Systematic Review and Meta- Analysis of Artificial Intelligence Tools in Medicine and Healthcare: Applications, Considerations, Limitations, Motivation and Challenges. Diagnostics. 2024 Jan 4;14(1):109.

[6]. Niazi SK. The coming of age of ai/ml in drug discovery, development, clinical testing, and manufacturing: The FDA perspectives. Drug Design, Development and Therapy. 2023 Dec31:2691-725.

[7]. Mishra S, Bhatt T, Kumar H, Jain R, Shilpi S, Jain V. Nanoconstructs for theranostic application in cancer: Challenges and strategies to enhance the delivery. Frontiers in Pharmacology. 2023 Mar 15;14:1101320.

[8]. Murray JD, Lange JJ, Bennett-Lenane H, Holm R, Kuentz M, O'Dwyer PJ, Griffin BT. Advancing algorithmic drug product development: Recommendations for machine learning approaches in drug formulation. European Journal of Pharmaceutical Sciences. 2023 Aug 9:106562.

[9]. Patel K. Ethical reflections on data-centric AI: balancing benefits and risks. International Journal of Artificial Intelligence Research and Development. 2024;2(1):1-7.

[10]. Husnain A, Rasool S, Saeed A, Hussain HK. Revolutionizing Pharmaceutical Research: Harnessing Machine Learning for a Paradigm Shift in Drug Discovery. International Journal of Multidisciplinary Sciences and Arts. 2023 Sep 27;2(2):149-57.

[11]. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches fordrug design: challenges and opportunities for the pharmaceutical industries. Molecular diversity. 2021 Oct 23:1-21.

[12]. Dong J, Wu Z, Xu H, Ouyang D. FormulationAI: a novel web-based platform for drug formulation design driven by artificial intelligence. Briefings in Bioinformatics. 2024 Jan 1;25(1):bbad419.

[13]. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity.2021 Aug;25:1315-60.

[14]. Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. Trends in Pharmacological Sciences. 2023 Jul 19.

[15]. Yin C, Zhu Y, Fei J, He X. A deep learning approach for intrusion detection using recurrent neural networks. Ieee Access. 2017 Oct 12;5:21954-61.

[16]. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery. 2004 Nov;3(11):935-49.

[17]. Ng YL, Salim CK, Chu JJ. Drug repurposing for COVID-19: Approaches, challenges and promising candidates. Pharmacology & therapeutics. 2021 Dec 1;228:107930.

[18]. Niazi SK, Mariam Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals. 2023 Dec 22;17(1):22.

[19]. Roy K, Kar S, Das RN. A primer on QSAR/QSPR modeling: fundamental concepts. Springer; 2015 Apr 11.

[20]. Fu L, Yang ZY, Yang ZJ, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. QSAR-assisted- MMPA to expand chemical transformation space for lead optimization. Briefings in Bioinformatics. 2021 Sep;22(5):bbaa374.

[21]. Bhatti UA, Tang H, Wu G, Marjan S, Hussain Deep learning with graph convolutional networks: An overview and latest applications in computational intelligence. International Journal of Intelligent Systems. 2023 Feb 28;2023:1-28.

[22]. Staszak M, Staszak K, Wieszczycka K, Bajek A, Roszkowski K, Tylkowski B. Machine learning in drug design: Use of artificial intelligence to explore the chemical structure– biological activity relationship. Wiley Interdisciplinary

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 899-906 www.ijprajournal.com ISSN: 2456-4494

Reviews: Computational Molecular Science. 2022 Mar;12(2):e1568.

[23]. Pasrija P, Jha P, Upadhyaya P, Khan M, Chopra M. Machine Learning and Artificial Intelligence: A Paradigm Shift in Big Data- Driven Drug Design and Discovery. Current Topics in Medicinal Chemistry. 2022 Aug 1;22(20):1692-727.

[24]. Muratov EN, Bajorath J, Sheridan RP, Tetko IV, Filimonov D, Poroikov V, Oprea TI, Baskin II, Varnek A, Roitberg A, Isayev O. QSAR without borders. Chemical Society Reviews. 2020;49(11):3525-64.

[25]. Mouchlis VD, Afantitis A, Serra A, Fratello M, Papadiamantis AG, Aidinis V, Lynch I, Greco D, Melagraki G. Advances in de novo drug design: from conventional to machine learning methods. International journal of molecular sciences. 2021 Feb 7;22(4):1676.

[26]. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020 Mar 18;25(6):1375.

[27]. Schneider G. Future de novo drug design. Molecular informatics. 2014 Jun;33(6-7):397- 402.

[28]. Han R, Yoon H, Kim G, Lee H, Lee Y. Revolutionizing medicinal chemistry: the applicationof artificial intelligence (AI) in early drug discovery. Pharmaceuticals. 2023 Sep 6;16(9):1259.

[29]. Niazi SK, Mariam Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals. 2023 Dec 22;17(1):22.

[30]. Duffy DJ. Problems, challenges and promises: perspectives on precision medicine. Briefings in bioinformatics. 2016 May 1;17(3):494-504.

[31]. Segall M. Advances in multiparameter optimization methods for de novo drug design. Expert opinion on drug discovery. 2014 Jul 1;9(7):803-17.

[32]. Pandey M, Fernandez M, Gentile F, Isayev O, Tropsha A, Stern AC, Cherkasov A. The transformational role of GPU computing and deep learning in drug discovery. Nature Machine Intelligence. 2022 Mar;4(3):211-21.

[33]. Akhtar S, Khan MK, Osama K. Machine learning approaches to rational drug design. Computer-Aided Drug Design. 2020:279-306.

[34]. Patel JR, Joshi HV, Shah UA, Patel JK. A review on computational software tools for drug design and discovery. Indo Global Journal of Pharmaceutical Sciences. 2022 Jan 29;12:53-81.

[35]. Zsoldos Z, Szabo I, Szabo Z, Johnson AP. Software tools for structure based rational drug design. Journal of Molecular Structure: THEOCHEM. 2003 Dec 1;666:659-65.

[36]. Geldenhuys WJ, Gaasch KE, Watson M, Allen DD, Van der Schyf CJ. Optimizing the use of open-source software applications in drug discovery. Drug discovery today. 2006 Feb 1;11(3-4):127-32.

[37]. Dangeti A, Bynagari DG, Vydani K. Revolutionizing Drug Formulation: Harnessing Artificial Intelligence and Machine Learning for Enhanced Stability, Formulation Optimization, and Accelerated Development.

[38]. Sousa AS, Serra J, Estevens C, Costa R, Ribeiro AJ. A quality by design approach in oral extended release drug delivery systems: where we are and where we are going?. Journal of Pharmaceutical Investigation. 2023 Mar;53(2):269-306.

[39]. Dawoud MH, Mannaa IS, Abdel-Daim A, Sweed NM. Integrating artificial intelligence with quality by design in the formulation of lecithin/chitosan nanoparticles of a poorly water-soluble drug. AAPS PharmSciTech. 2023 Aug 8;24(6):169.

[40]. Tosca EM, Bartolucci R, Magni P. Application of artificial neural networks to predict the intrinsic solubility of drug-like molecules. Pharmaceutics. 2021 Jul 20;13(7):1101.